NCT05546567Active, not recruiting
NOPARK Open Label Extension Study
Source: ClinicalTrials.gov · Last updated 30 May 2025
Brief summary (registry, in English)
This protocol describes the NOPARK Open Label Extension Study. The NOPARK Open Label Extension study is an optional extension of the clinical phase II NOPARK study. Participants who have been included in the NOPARK study will upon completing their participation in the NOPARK study (i.e., after 52 weeks) be offered to receive the study drug Nicotinamide Riboside (NR) 1200 mg P.O. per day, until the NOPARK trial is completed, and the data analyzed with a conclusion of the primary outcome. Individuals enrolled into the NOPARK Open Label Extension Study will be followed with yearly visits. The goal of the NOPARK Open Label Extension Study is to monitor long term safety and study long term neuroprotective and other biological effects of NR use.
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 400 (estimated)
- First submitted
- 15 Sept 2022
- Start date
- 28 Sept 2022
- Primary completion date
- 20 Jun 2025
- Lead sponsor
- Haukeland University Hospital
- Diseases
- Parkinson disease
- NCT number
- NCT05546567
What you commit to
- Study type: Interventional
- Planned participants: 400
- From 28 Sept 2022 to the primary completion date, 20 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Current use of vitamin B3 supplementation or NR supplementation - other than in relation to the NOPARK study
- Known allergic reactions to components of the NR
- Physical or psychiatric illness that makes them unavailable for follow-up and participation.
Who the study is looking for
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Participated in the NOPARK study
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Haukeland University Hospital Coordinator of this site? Confirm its status | Bergen | Norway | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.